排序方式： 共有156条查询结果，搜索用时 15 毫秒
11.
12.
13.
TIPS术前门静脉MRA评价初探 总被引：2，自引：0，他引：2
目的：探讨门静脉ＭＲＡ对ＴＩＰＳ病例术前评价的价值。材料和方法：７例门脉高压患者在ＴＩＰＳ术前经２Ｄ ＴＯＦ及２Ｄ ＰＣ评价门脉的开放性、血流方向以及门脉主干及其分支与肝静脉的空间关系，以及静脉曲张情况。结果：本组７例ＴＩＰＳ术前门脉ＭＲＡ均满意显示门脉、分叉部以及肝静脉各支，所得结果与造影相符。食管静脉、胃冠状静脉、脾门静脉曲张分别为７、４、３例。脐静脉开放２例。结论：门脉ＭＲＡ是一种有价值的无损伤性检查技术，对ＴＩＰＳ术前门静脉评价将起重要作用。 相似文献
14.
Georges M. Haidar Taylor D. Hicks David S. Strosberg Hosam F. El-Sayed Mark G. Davies 《Journal of vascular surgery》2017,65(6):1824-1829
Objective
Endografts (eg, aortic aneurysm device or covered stent) are increasingly being used to temporize or treat arterial and graft infections in inaccessible areas, in patients with compromised anatomy, or in the presence of active bleeding or rupture. This summary examines the evidence for “in situ” endografting in the treatment these conditions.Methods
A two-level search strategy of the literature (MEDLINE, PubMed, Google Scholar, and The Cochrane Library) was performed for relevant articles listed between January 2000 and December 2015. The review was confined to patients with primary and secondary bacterial or viral arterial infections, with or without fistulization and infection of bypass grafts and arteriovenous accesses. For the purposes of this summary, endografts can be considered to be an aortic aneurysm device or a covered stent.Results
There are no societal guidelines. Endografts have been successfully applied to mycotic arterial aneurysms, aortoenteric, aortobronchial, and arterioureteric fistulae, and to anastomotic bleeds secondary to infection. Multiple reports indicate success at the control of hemorrhage in all locations. Short-term outcomes are good, but fatal infection-related complications, especially if antibiotic therapy is halted, are well reported and necessitate a more definitive plan for the long term.Conclusions
Stent grafts remain an important and viable option for the treatment of mycotic aneurysms, aortoesophageal and aortobronchial fistulae, and infected pseudoaneurysms in anatomically or technically inaccessible locations. In patients with a short life span (<6 months), no further intervention is generally required. In patients with a predicted life span >6 months, careful consideration should be given to a more definitive procedure. Life-long appropriate antibiotic therapy is strongly recommended for any patient receiving an endograft in an infected field. 相似文献15.
16.
17.
18.
19.
Joseph Hanna Yeni H. Yücel Xun Zhou Emily Mathieu Luz A. Paczka-Giorgi Neeru Gupta 《Canadian journal of ophthalmology. Journal canadien d'ophtalmologie》2018,53(4):391-401
Objective
To assess retinal blood vessels in a live retinitis pigmentosa (RP) model with rd1 mutation and green fluorescent protein (GFP) expressed in vascular endothelium.Methods
Homozygous (hm) Tie2-GFP mice with rd1 mutation and known retinal degeneration were crossed with wild-type CD1 mice to generate control heterozygous (ht) Tie2-GFP mice. The retinas of 16 live hm mice were evaluated at 2 weeks and 3, 5, and 8 months of age, and compared with age-matched control ht and CD1 mice by optical coherence tomography (OCT) and confocal scanning laser ophthalmoscopy (cSLO). Fluorescence intensity was measured and compared between strains at 3, 5, and 8 months. In vivo findings were validated by immunostaining with collagen IV and isolectin histopathology.Results
All hm Tie2-GFP mice showed progressive outer retinal degeneration by OCT. Loss of small branches of blood vessels and then larger main vessels was seen by cSLO. Retinal tissue and vessels were preserved in control ht mice. At all ages, measurements of fluorescence intensity were reduced in hm compared with ht mice (p < 0.001). In all strains, intensity at 8 months was reduced compared with 3 months (p < 0.001) and 5 months (p = 0.021). Histopathological studies confirmed in vivo findings and revealed a pattern of blood vessel regression in the deep plexus, followed by intermediate and superficial retinal plexuses.Conclusions
This is the first evidence of progressive loss of retinal blood vessels in a live mouse model of RP. These findings may be highly relevant to understanding retinal degeneration in RP to prevent blindness. 相似文献20.
Carine E. Hamo Christopher O&#x;Connor Marco Metra James E. Udelson Mihai Gheorghiade Javed Butler 《Journal of cardiac failure》2018,24(11):783-792
The prevalence of heart failure continues to grow, and this is accompanied by an increase in hospitalization for acute heart failure. Hospitalization for heart failure results in a trajectory shift of the syndrome and is associated with worsening outcomes, increased mortality risk, and high costs. Numerous clinical trials over the past 2 decades have had limited success, with no single agent shown to improve mortality risk. The lack of success is multifactorial and in part related to inadequate targets and end points selected for intervention, underscoring the need to better understand and define the pathophysiology of acute heart failure. To better inform future drug development, this review critically explores the short-term end points and outcomes that previous phase III acute heart failure trials have examined. 相似文献